Neuroderm Revenue and Competitors

Rehovot,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Neuroderm's estimated annual revenue is currently $40.8M per year.(i)
  • Neuroderm's estimated revenue per employee is $201,000

Employee Data

  • Neuroderm has 203 Employees.(i)
  • Neuroderm grew their employee count by -7% last year.

Neuroderm's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Neuroderm?

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients' lives. NeuroDerm's technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

keywords:N/A

N/A

Total Funding

203

Number of Employees

$40.8M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neuroderm News

2022-03-30 - AAN Spotlight: Multiple System Atrophy, Migraine, ALS and ...

NeuroDerm's Drug-Device Combo Product for Parkinson's Disease. NeuroDerm presented positive, long-term safety and tolerability data for...

2022-03-30 - BeyoND Phase 2b Data Indicates ND0612 Has a Positive ...

NeuroDerm presents data at 2022 American Academy of Neurology Annual Meeting. Long-term safety data from the Phase 2b BeyoND study...

2022-03-30 - Global Roundup: Ginkgo/Microba Autoimmune Pact and New ...

NeuroDerm Ltd: Israel-based NeuroDerm announced positive, long-term data for Parkinson's disease-aimed asset ND0612 at the American Academy...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$82.6M278-5%N/A